NeoImmuneTech, Inc.
Develops NT-I7, a T cell-amplifying immunotherapy for cancer and infectious diseases.
950220 | KO
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 2400 Research Boulevard, Suite 250, Rockville, MD 20850, Rockville
- Website:
- https://www.neoimmunetech.com/en
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
NeoImmuneTech, Inc. is a clinical-stage, T cell-focused biotechnology company dedicated to developing novel immuno-therapeutics. Founded in 2014, the company's core technology is NT-I7 (efineptakin alfa), a long-acting human interleukin-7 designed to amplify the quantity and enhance the functionality of T cells. This proprietary asset is being developed to treat various cancers and infectious diseases. NeoImmuneTech's research and development efforts focus on exploring NT-I7 as both a monotherapy and in combination with other treatments, aiming to expand the horizons of immuno-oncology and address unmet medical needs.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for NeoImmuneTech, Inc. and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-09-18 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 25.0 KB | |
| 2025-09-18 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 94.2 KB | |
| 2025-09-16 00:00 |
Share Issue/Capital Change
증권발행결과(자율공시) (주주배정 후 실권주 일반공모)
|
Korean | 7.8 KB | |
| 2025-09-16 00:00 |
Share Issue/Capital Change
증권발행실적보고서
|
Korean | 90.0 KB | |
| 2025-09-15 00:00 |
Share Issue/Capital Change
유상증자또는주식관련사채등의청약결과(자율공시) (주주배정후 실권주 일반공모)
|
Korean | 11.0 KB | |
| 2025-09-10 00:00 |
Share Issue/Capital Change
유상증자또는주식관련사채등의청약결과(자율공시) (주주배정후 실권주 일반공모)
|
Korean | 9.6 KB | |
| 2025-09-04 00:00 |
Share Issue/Capital Change
유상증자최종발행가액확정 (주주배정후 실권주 일반공모)
|
Korean | 11.3 KB | |
| 2025-09-04 00:00 |
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
|
Korean | 38.3 KB | |
| 2025-09-04 00:00 |
Registration Form
[발행조건확정]증권신고서(증권예탁증권)
|
Korean | 218.3 KB | |
| 2025-09-04 00:00 |
Prospectus
[기재정정]투자설명서
|
Korean | 2.7 MB | |
| 2025-08-21 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.2 KB | |
| 2025-08-21 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.2 KB | |
| 2025-08-21 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.2 KB |
Automate Your Workflow. Get a real-time feed of all NeoImmuneTech, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for NeoImmuneTech, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
